LifeMD (LFMD) AI Stock Analysis

• Market Cap: $297.78M
• Dividend Yield: N/A
• Average Volume (3M): 2.22M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: 37.74%
• EPS Growth: 69.79%
• Country: US
• Employees: 304
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -0.06
• Shares Outstanding: 47,417,393
• 10 Day Avg. Volume: 1,130,674
• 30 Day Avg. Volume: 2,216,614
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.99
• Enterprise Value/Revenue: 2.55
• Enterprise Value/Gross Profit: 2.76
• Enterprise Value/Ebitda: 69.31
• 1Y Price Target: $15.00
• Price Target Upside: 147.52% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 48 Neutral
• Price Target: $6.50 ▲(7.26% Upside)

LifeMD's overall stock score is primarily impacted by its financial performance, which is challenged by declining revenue growth and high leverage. While there are positive aspects such as strong free cash flow growth and strategic initiatives highlighted in the earnings call, the stock's valuation and technical indicators suggest caution. The company's efforts to expand its telehealth and behavioral health offerings are promising, but financial risks and profitability concerns weigh heavily on the score.

Positive Factors

Market Position

LifeMD's comprehensive care platform and new product offerings are anticipated to enhance its market position.

New Services

The company is preparing to launch its virtual behavioral health offering and women’s health specialty offering, indicating future expansion and diversification of services.

Subscriber Growth

The Telehealth active subscriber base grew by 27% year-over-year, highlighting the company's expanding customer reach.

Negative Factors

Business Segment Performance

There was a dip for the RexMD business (men’s telehealth platform brand) during the quarter, which represents a significant portion of the Telehealth revenue.

Revenue Guidance

Top- and bottom-line miss in 2Q25; 2025 guidance lowered.

Risks and Challenges

Risks include lower than projected growth of telehealth revenue, inability to acquire and retain new patients, and higher than expected competition, which could affect the company's performance.

LifeMD Business Overview & Revenue Model

Company Description

LifeMD (LFMD) is a telehealth company that specializes in providing a range of virtual healthcare services, primarily focusing on chronic disease management, sexual health, and weight loss. The company leverages advanced technology to connect patients with licensed healthcare providers, offering personalized treatment plans and medications that are delivered directly to patients' homes. LifeMD's core products include telehealth consultations, prescription medications, and subscription-based health programs, catering to the growing demand for convenient and accessible healthcare solutions.

How the Company Makes Money

LifeMD generates revenue through multiple streams, primarily by charging patients for telehealth consultations and the sale of prescription medications. The company operates on a direct-to-consumer model, allowing it to reach a broad audience seeking convenient healthcare services. Significant revenue comes from subscription programs where patients pay for ongoing access to healthcare services and personalized treatment plans. Additionally, LifeMD may benefit from strategic partnerships with pharmacies and healthcare providers, which can enhance its service offerings and expand its customer base, further contributing to its earnings.

LifeMD Financial Statement Overview

Summary

LifeMD faces significant challenges with declining revenue growth and negative profitability margins. The balance sheet is heavily leveraged, posing financial risks. However, the company has shown strong free cash flow growth, which is a positive indicator of cash generation capability. Overall, while there are strengths in cash flow, the financial health of the company is concerning due to high leverage and negative profitability.

Income Statement

LifeMD has shown a significant decline in revenue growth with a TTM (Trailing-Twelve-Months) revenue growth rate of -95%. The gross profit margin remains strong at 91.97%, indicating efficient cost management. However, the net profit margin is negative at -5.21%, reflecting ongoing profitability challenges. EBIT and EBITDA margins are also weak, suggesting operational inefficiencies.

Balance Sheet

The company's balance sheet reveals a high debt-to-equity ratio of -10.78, indicating significant leverage and potential financial risk. Return on equity is positive at 2.33%, but this is due to negative equity, which is a concerning sign. The equity ratio is not favorable, suggesting a reliance on debt financing.

Cash Flow

LifeMD's cash flow statement shows a remarkable free cash flow growth of 318.98% in the TTM period, indicating improved cash generation. The operating cash flow to net income ratio is 0.25, and the free cash flow to net income ratio is 0.21, reflecting moderate cash flow efficiency despite negative net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	232.45M	212.45M	152.55M	119.03M	92.88M	37.29M
Gross Profit	215.05M	242.40M	133.65M	100.37M	74.88M	28.39M
EBITDA	8.55M	-6.65M	-8.21M	-39.61M	-53.95M	-57.48M
Net Income	-6.70M	-18.88M	-20.60M	-45.02M	-61.32M	-60.52M
Balance Sheet
Total Assets	73.56M	72.46M	58.48M	25.67M	49.92M	13.05M
Cash, Cash Equivalents and Short-Term Investments	36.23M	35.00M	33.15M	3.96M	41.33M	9.18M
Total Debt	22.05M	25.10M	18.93M	4.13M	1.85M	1.06M
Total Liabilities	73.18M	76.51M	52.91M	32.97M	24.10M	13.88M
Stockholders Equity	-1.78M	-5.49M	3.51M	-6.83M	26.85M	1.35M
Cash Flow
Free Cash Flow	13.27M	5.98M	86.95K	-35.83M	-36.49M	-12.53M
Operating Cash Flow	19.48M	17.51M	8.82M	-22.94M	-33.09M	-12.13M
Investing Cash Flow	-12.78M	-11.54M	-8.73M	-13.91M	-3.40M	-798.14K
Financing Cash Flow	-6.17M	-4.12M	29.10M	-528.20K	68.64M	21.00M

LifeMD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFMD, the sentiment is Negative. The current price of 6.06 is below the 20-day moving average (MA) of 6.40, below the 50-day MA of 9.28, and below the 200-day MA of 7.62, indicating a bearish trend. The MACD of -0.86 indicates Negative momentum. The RSI at 33.49 is Neutral, neither overbought nor oversold. The STOCH value of 25.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFMD.

LifeMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OSUR	57 Neutral	$236.23M	25.27	-12.65%	―	-49.35%	-285.61%
WBA	55 Neutral	$10.37B	―	-60.49%	8.35%	6.22%	-8.21%
PETS	53 Neutral	$62.80M	285.05	0.36%	―	-10.82%	―
Sector *	51 Neutral	$7.95B	-0.40	-41.67%	2.21%	22.29%	-1.85%
FHTX	49 Neutral	$326.18M	―	322.49%	―	-31.30%	36.26%
LFMD	48 Neutral	$297.78M	―	301.60%	―	37.74%	69.79%
AVIR	47 Neutral	$267.43M	―	-32.38%	―	―	23.24%

LifeMD Corporate Events

LifeMD Appoints Shayna Webb Dray as COO

On July 31, 2025, LifeMD announced the appointment of Shayna Webb Dray as Chief Operating Officer, effective March 27, 2025. With over 15 years of experience in operations and supply chain management, Webb Dray has been instrumental in LifeMD’s growth, previously serving as Senior Vice President of Operations. Her leadership is expected to support LifeMD’s expansion into new verticals and enhance patient care quality. Additionally, LifeMD expanded the roles of two other executives, promoting Jessica Friedeman to Chief Marketing and Product Officer and Jacob Ellison to Chief Analytics Officer, reflecting the company’s focus on internal talent to drive innovation and growth.

The most recent analyst rating on (LFMD) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.

LifeMD Stockholders Approve Directors and Accounting Firm

On June 13, 2025, LifeMD, Inc. held its annual meeting of stockholders where a quorum was present. During this meeting, stockholders approved the election of seven directors to serve until the next annual meeting and ratified the selection of CBIZ CPAs, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (LFMD) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.